Gil Y. Roth, Contract Pharma05.30.12
In April, I met up with James (Jim) Botkin at INTERPHEX in New York City to ask him how the merger of Alkermes Inc. and Elan Drug Technologies, which took place last September, has changed the type of business opportunities they now seek. What emerged from our conversation was a deeper understanding of the company’s business model, the ‘fit’ of the merged entity and the importance now of their manufacturing expertise. With 40 years' experience in contracting services under his belt, Jim still passionately believes in the importance of fostering and maintaining deep and long-term strategic relationships with partners. —GYR
Contract Pharma: How’s the integration going, folding Elan Drug Technologies (EDT) into Alkermes?
Jim Botkin: The merger closed in September 2011, and I think it’s gone extremely well, for a couple of reasons. The purpose of the merger was to bring together two companies that were very compatible with like mindsets regarding drug development and manufacturing excellence. Both companies have a heritage of applying proprietary
Contract Pharma: How’s the integration going, folding Elan Drug Technologies (EDT) into Alkermes?
Jim Botkin: The merger closed in September 2011, and I think it’s gone extremely well, for a couple of reasons. The purpose of the merger was to bring together two companies that were very compatible with like mindsets regarding drug development and manufacturing excellence. Both companies have a heritage of applying proprietary
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
